Skip to content

Propofol + Remifentanil vs. Propofol + Dexmedetomidine in Adolescent Idiopathic Scoliosis Patients Having Spine Surgery

A Prospective Study Comparing Total Intravenous Anesthesia With Propofol and Remifentanil vs. Propofol and Dexmedetomidine in Adolescent Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion and Instrumentation

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06096181
Enrollment
13
Registered
2023-10-23
Start date
2023-12-20
Completion date
2024-12-24
Last updated
2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Idiopathic Scoliosis, Dexmedetomidine, Multimodal Analgesia, Opioid Induced Hyperalgesia, Posterior Spinal Fusion, Remifentanil

Brief summary

Patients with Adolescent Idiopathic Scoliosis may need surgery to correct their scoliosis. General anesthesia is required for this surgery, and a multimodal analgesic regimen using combinations of opioid and non-opioid medications is the standard of care. The purpose of this study is to compare two combinations of total intravenous anesthetic medications in children with Adolescent Idiopathic Scoliosis having posterior spinal fusion surgery. Participants in the study will be randomly selected to receive either Propofol and Remifentanil or Propofol and Dexmedetomidine as their total intravenous anesthesia (TIVA). TIVA is favored over gas anesthesia because gas anesthesia can affect the neurological monitoring necessary for this surgery. The first combination (Propofol + Remifentanil) is the most common one used for this surgery at our institution, and the second combination (Propofol + Dexmedetomidine) is more commonly used in adult spine surgery. Though Dexmedetomidine is not approved for pediatric use by the FDA, it is widely used in pediatric patients for procedural sedation and surgical anesthesia in the US and worldwide. Both anesthetic combinations are used safely in adult and pediatric patients at our institution. Although remifentanil works fast and is an excellent pain medication during surgery, there are reports that it's use can cause increased pain sensitivity and greater need for narcotic pain medication after surgery. This phenomenon is known as opioid-induced hyperalgesia. The investigators hypothesize that avoiding the use of remifentanil in the TIVA by using dexmedetomidine could avoid OIH and thus result in superior postop pain control. Our study's primary goal is to measure the total opioid consumption on postoperative days (POD)# 0 and 1. Our secondary goals are to measure the pain scores on a visual analog scale (VAS) on POD# 0 and 1, measure the time it takes for participants to move their feet to command when surgery is done, and measure the time it takes for participants to be extubated when surgery is done. By comparing these measurements, the investigators hope to find out if there is any significant difference between the two TIVAs in terms of postop opioid requirements, pain scores, and time to wake up from anesthesia. The investigators hope that our study gives us more knowledge on how to better treat postoperative pain in children who have spine surgery to correct their

Detailed description

Patients with Adolescent Idiopathic Scoliosis (AIS) may need surgery to correct their scoliosis. General anesthesia is required for this surgery, and a multimodal analgesic regimen using combinations of opioid and non-opioid medications is the standard of care. Total intravenous anesthesia (TIVA) is the usual anesthetic technique of choice. The purpose of this study is to compare two combinations of TIVA medications in children AIS having posterior spinal fusion surgery. The most common TIVA for this surgery at our institution is Propofol + Remifentanil. Remifentanil is a popular choice because of its rapid onset, extremely short context-sensitive half-life, potency, and its rapid recovery from drug effect. However, an important concern with intraoperative remifentanil infusion is the possible development of acute opioid-induced hyperalgesia (OIH). In adults, OIH is a well-documented feature linked to intraoperative remifentanil administration, manifesting as increased postoperative analgesic requirement and paradoxical increase in sensitivity to painful stimuli. In pediatric patients, the phenomenon is not as well characterized. An alternative TIVA that is very commonly used for adult spine surgery is propofol + dexmedetomidine (DEX). DEX is a highly selective alpha2-adrenergic receptor agonist with sedative, analgesic, and sympatholytic properties. Despite the lack of FDA approval for pediatric use, DEX is widely used off-label in pediatric patients in the US and worldwide and has previously been shown to be safe and efficacious for various clinical indications including procedural sedation, craniotomy-awake-surgery, cardiac surgery, and posterior spinal fusion for scoliosis. DEX is currently used safely in pediatric and adult spine patients in our institution. The most common adverse effect is intraoperative bradycardia. Participants will be randomized to receive one of the two TIVAs to see if one or the other results in lower opioid consumption, and lower Visual Analog Scale (VAS) pain scores in the post-operative period (POD# 0 and 1). The investigators hypothesize that the use of DEX will avoid OIH and this will lead to less opioid consumption in the postoperative period, and superior postoperative pain control. The investigators also hope to show that the use of DEX will not significantly prolong time to moving feet to command and extubation at conclusion of surgery.

Interventions

DRUGRemifentanil TIVA

Remifentanil is more commonly used in the TIVA combination for pediatric patients having this surgery.

DRUGDexmedetomidine TIVA

Dexmedetomidine is less commonly used in the TIVA combination for pediatric patients having this surgery.

Propofol is an anesthetic drug that causes sleep during surgery.

Sponsors

Cedars-Sinai Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Masking description

The following persons are masked: 1. Participant and parents 2. Pediatric Intensive Care Unit (PICU) staff taking care of patient postoperatively 3. Surgeon

Eligibility

Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 12-18 years old * American Society of Anesthesiology Physical Status Classification (ASA Class) 1 and 2 * Have diagnosis of Adolescent Idiopathic Scoliosis * Undergoing Posterior Spinal Fusion with instrumentation for scoliosis correction * Matched on age, sex, and the number of vertebral levels fused

Exclusion criteria

* Neuromuscular scoliosis * Allergy to any of the multi-modal analgesia regimen drugs * Use of serotonergic drugs, monoamine oxidase inhibitors (MAOI), mixed agonist/antagonist opioid analgesics

Design outcomes

Primary

MeasureTime frameDescription
Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1Post Op Day# 0 and 1Measure the median total opioid medications needed by the participants (IV and oral) after surgery on post operative days # 0 and 1.

Secondary

MeasureTime frameDescription
Mean VAS Pain Score on POD# 0 and 1Post Op Day# 0 and 1Measure the mean pain score of the participant on a visual analog pain scale. The VAS has two end points representing 0 (no pain) and 10 (worst pain ever). It is reported at our institution as a number between 0 and 10.
Time From Skin Closure to Participant Being Able to Move Their Feet on Command (Mins)Intraoperative (day of surgery)Measure the median time (mins) from completion of surgical skin closure to the participant being able to move their feet to command.
Time From Skin Closure to ExtubationIntraoperative (day of surgery)Measure the median time (mins) from completion of surgical skin closure to extubation.

Countries

United States

Participant flow

Recruitment details

Study participants were recruited via investigator's review of medical records of their patients, approached by study team during inpatient or outpatient clinic visit, or referred to research team by their treating physician. Patients were enrolled from 12/20/2023 to 12/24/2024.

Participants by arm

ArmCount
Propofol + Remifentanil
Participants are randomly selected to receive Propofol + Remifentanil TIVA as their anesthesia. Dose of IV Propofol is 100-200 mcg/kg/min and dose of Remifentanil is 0.2-0.5 mcg/kg/min. TIVA is titrated to keep bispectral index (BIS) \< 55-60 to ensure patient is asleep.
7
Propofol + Dexmedetomidine
Participants are randomly selected to receive Propofol + Dexmedetomidine as their anesthesia. Dose of Propofol is 100-200 mcg/kg/min and dose Dexmedetomidine is ) 0.2-0.7 mcg/kg/hr. TIVA is titrated to beep bispectral index (BIS) \< 55-60 to ensure patient is asleep.
6
Total13

Baseline characteristics

CharacteristicPropofol + RemifentanilPropofol + DexmedetomidineTotal
Age, Continuous16 Years17.2 Years16.5 Years
Race/Ethnicity, Customized
Race/Ethicity
Hispanic/Latino
1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Race/Ethicity
White
6 Participants6 Participants12 Participants
Sex: Female, Male
Female
6 Participants3 Participants9 Participants
Sex: Female, Male
Male
1 Participants3 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 6
other
Total, other adverse events
0 / 70 / 6
serious
Total, serious adverse events
0 / 70 / 6

Outcome results

Primary

Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1

Measure the median total opioid medications needed by the participants (IV and oral) after surgery on post operative days # 0 and 1.

Time frame: Post Op Day# 0 and 1

ArmMeasureGroupValue (MEDIAN)Dispersion
Propofol + RemifentanilTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 036.30 MMEInter-Quartile Range 71.9
Propofol + RemifentanilTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 157.5 MME
Propofol + DexmedetomidineTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 070.5 MMEInter-Quartile Range 66.98
Propofol + DexmedetomidineTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 148 MME
Primary

Total Opioid Consumption (IV and PO in MME) on POD# 0 and 1

Measure the mean total opioid medications needed by the participants (IV and oral) after surgery on post operative days # 0 and 1.

Time frame: Post Op Day# 0 and 1

ArmMeasureGroupValue (MEAN)Dispersion
Propofol + RemifentanilTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 075.12 MMEStandard Deviation 71.58
Propofol + RemifentanilTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 154.38 MMEStandard Deviation 28.12
Propofol + DexmedetomidineTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 088.93 MMEStandard Deviation 66.98
Propofol + DexmedetomidineTotal Opioid Consumption (IV and PO in MME) on POD# 0 and 1MME POD 152.20 MMEStandard Deviation 27.4
Secondary

Mean VAS Pain Score on POD# 0 and 1

Measure the mean pain score of the participant on a visual analog pain scale. The VAS has two end points representing 0 (no pain) and 10 (worst pain ever). It is reported at our institution as a number between 0 and 10.

Time frame: Post Op Day# 0 and 1

ArmMeasureGroupValue (MEAN)Dispersion
Propofol + RemifentanilMean VAS Pain Score on POD# 0 and 1VAS POD 03.39 Visual Analog Pain Scale ScoreStandard Deviation 2.3
Propofol + RemifentanilMean VAS Pain Score on POD# 0 and 1VAS POD 13.32 Visual Analog Pain Scale ScoreStandard Deviation 2.81
Propofol + DexmedetomidineMean VAS Pain Score on POD# 0 and 1VAS POD 02.23 Visual Analog Pain Scale ScoreStandard Deviation 1.4
Propofol + DexmedetomidineMean VAS Pain Score on POD# 0 and 1VAS POD 13.21 Visual Analog Pain Scale ScoreStandard Deviation 0.98
Secondary

Time From Skin Closure to Extubation

Measure the median time (mins) from completion of surgical skin closure to extubation.

Time frame: Intraoperative (day of surgery)

ArmMeasureValue (MEDIAN)
Propofol + RemifentanilTime From Skin Closure to Extubation15 Minutes
Propofol + DexmedetomidineTime From Skin Closure to Extubation22 Minutes
Secondary

Time From Skin Closure to Participant Being Able to Move Their Feet on Command (Mins)

Measure the median time (mins) from completion of surgical skin closure to the participant being able to move their feet to command.

Time frame: Intraoperative (day of surgery)

ArmMeasureValue (MEDIAN)
Propofol + RemifentanilTime From Skin Closure to Participant Being Able to Move Their Feet on Command (Mins)14 Minutes
Propofol + DexmedetomidineTime From Skin Closure to Participant Being Able to Move Their Feet on Command (Mins)21.5 Minutes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026